India's pharmaceutical companies to report mixed results as domestic growth offsets pricing pressures

India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance.

ET Intelligence Group: India's leading pharmaceutical companies are expected to report a mixed performance in the September quarter, with growth largely driven by domestic formulations, specialty products, and emerging markets.

On the other hand, pricing pressure, generic competition, elevated raw material costs and a high base in the US business are likely to weigh on some players. Sun Pharmaceutical Industries, Aurobindo Pharma, Torrent Pharmaceuticals and Divi's Laboratories are expected to be among the stronger performers whereas Dr Reddy's Laboratories, Lupin and Cipla may be under pressure due to the absence of high-margin opportunities seen in the previous year and increased competition in key products.